Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis

38 p.-5 fig.-2 tab.

Detalles Bibliográficos
Autores: Martínez-González, Loreto, Martínez Gil, Ana
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/308825
Acceso en línea:http://hdl.handle.net/10261/308825
Access Level:acceso abierto
Palabra clave:Amyotrophic lateral sclerosis
Clinical trials
Emerging pharmacological therapies
Kinase inhibitors
New drugs
id ES_ca4585608156cc2bd57a8a42a83518a2
oai_identifier_str oai:digital.csic.es:10261/308825
network_acronym_str ES
network_name_str España
repository_id_str
spelling Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosisMartínez-González, LoretoMartínez Gil, AnaAmyotrophic lateral sclerosisClinical trialsEmerging pharmacological therapiesKinase inhibitorsNew drugs38 p.-5 fig.-2 tab.Introduction: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by motoneuron death with a median survival time of 3-5 years since disease onset. There are no effective treatments to date. However, a variety of innovative investigational drugs and biological-based therapies are under clinical development.Areas covered: This review provides an overview of the clinical investigational small molecules as well as a brief summary of the biological-based therapies that are currently undergoing clinical trials for the treatment of ALS. All the data were obtained from ClinicalTrials.gov (registered through November 1).Expert opinion: Drug discovery for ALS is an active and evolving field, where many investigational clinical drugs are in different trials. There are several mechanisms of action supporting all these new therapies, although proteostasis is gaining stage. Probably, small orally bioavailable molecules able to recover functional TDP-43 homeostasis may have solid chances to modify ALS progression.This manuscript was funded by La Caixa and Luzón Foundation (grant HR21-00931) and National Health Institute ISCiii (grant CB18/05/00040, CIBERNED).Peer reviewedTaylor & FrancisFundación la CaixaFundación Francisco LuzónInstituto de Salud Carlos IIIMartínez-González, Loreto [0000-0003-4593-4889]Martínez, Ana [0000-0002-2707-8110]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Postprintinfo:eu-repo/semantics/acceptedVersionhttp://hdl.handle.net/10261/308825reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1080/13543784.2023.2178416Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3088252026-05-22T06:33:51Z
dc.title.none.fl_str_mv Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
title Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
spellingShingle Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
Martínez-González, Loreto
Amyotrophic lateral sclerosis
Clinical trials
Emerging pharmacological therapies
Kinase inhibitors
New drugs
title_short Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
title_full Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
title_fullStr Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
title_full_unstemmed Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
title_sort Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
dc.creator.none.fl_str_mv Martínez-González, Loreto
Martínez Gil, Ana
author Martínez-González, Loreto
author_facet Martínez-González, Loreto
Martínez Gil, Ana
author_role author
author2 Martínez Gil, Ana
author2_role author
dc.contributor.none.fl_str_mv Fundación la Caixa
Fundación Francisco Luzón
Instituto de Salud Carlos III
Martínez-González, Loreto [0000-0003-4593-4889]
Martínez, Ana [0000-0002-2707-8110]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Amyotrophic lateral sclerosis
Clinical trials
Emerging pharmacological therapies
Kinase inhibitors
New drugs
topic Amyotrophic lateral sclerosis
Clinical trials
Emerging pharmacological therapies
Kinase inhibitors
New drugs
description 38 p.-5 fig.-2 tab.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Postprint
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/308825
url http://hdl.handle.net/10261/308825
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1080/13543784.2023.2178416
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419465491349504
score 15,812429

Similares en LA Referencia